fluorouracil has been researched along with Carcinoma, Lobular in 78 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Carcinoma, Lobular: A type of BREAST CANCER where the abnormal malignant cells form in the lobules, or milk-producing glands, of the breast.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Women with axillary node-positive or high-risk node-negative breast cancer were randomly assigned to receive either three cycles of docetaxel and capecitabine (TX) followed by three cycles of cyclophosphamide, epirubicin, and capecitabine (CEX; n = 753) or three cycles of docetaxel (T) followed by three cycles of cyclophosphamide, epirubicin, and fluorouracil (CEF; n = 747)." | 9.16 | Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. ( Ahlgren, J; Asola, R; Auvinen, P; Bono, P; Helle, L; Huovinen, R; Joensuu, H; Jukkola-Vuorinen, A; Kataja, V; Kellokumpu-Lehtinen, PL; Kokko, R; Leinonen, M; Lindman, H; Nilsson, G; Nyandoto, P; Paija, O; Pajunen, M; Poikonen, P; Tanner, M; Villman, K, 2012) |
| "To determine rates of pathologic complete response (pCR) and near-complete response (npCR) in operable early-stage breast cancer using neoadjuvant capecitabine plus docetaxel, with or without trastuzumab, and investigate biomarkers of pathologic response." | 9.16 | TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab. ( Avisar, E; Glück, S; McKenna, EF; Perou, CM; Ross, JS; Royce, M; Wu, L, 2012) |
| "After breast cancer surgery, women with lymph node-positive disease were randomly assigned to treatment with fluorouracil, epirubicin, and cyclophosphamide (FEC) or with FEC followed by weekly paclitaxel (FEC-P)." | 9.13 | Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. ( Adrover, E; Alba, E; Almenar, S; Alvarez, I; Alvarez, JV; Antón, A; Aranda, E; Baena, JM; Calvo, L; Crespo, C; de Alava, E; García Puche, JL; Gonzalez, S; González-Palacios, JF; Gracia Marco, JM; Guitián, MD; Lluch, A; López García-Asenjo, JA; López-Vega, JM; Martín, M; Mayordomo, JI; Mel, JR; Modolell, A; Munárriz, B; Palacios, J; Pelegrí, A; Plazaola, A; Ramos, M; Rodríguez, CA; Rodríguez-Lescure, A; Ruiz, A; Ruiz-Borrego, M; Sánchez-Rovira, P; Seguí, MA; Vera, F, 2008) |
| "The purpose was to compare disease-free survival (DFS) between epirubicin-based chemoendocrine therapy and tamoxifen alone in one to three node-positive (N1-3), estrogen-receptor-positive (ER+), postmenopausal early breast cancer (EBC) patients." | 9.12 | Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 ( Bonneterre, J; Campone, M; Fargeot, P; Kerbrat, P; Luporsi, E; Monnier, A; Montcuquet, P; Namer, M; Roché, H; Romestaing, P, 2006) |
| "Phase II study evaluating efficacy and safety of combined oxaliplatin/fluorouracil (5-FU) in taxane-pretreated advanced and metastatic breast cancer (ABC) patients." | 9.10 | Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients. ( Chollet, P; Chouaki, N; Cottu, P; Culine, S; Dieras, V; Gamelin, E; Mackenzie, S; Marty, M; Misset, JL; Spielmann, M; Tubiana-Hulin, M; Vannetzel, JM; Zelek, L, 2002) |
| "To study the outcomes of adjuvant goserelin combined with tamoxifen (GosTam) compared to chemotherapy followed by tamoxifen (ChemTam) in premenopausal patients with early stage, luminal A breast cancer." | 7.83 | Goserelin plus tamoxifen compared to chemotherapy followed by tamoxifen in premenopausal patients with early stage-, lymph node-negative breast cancer of luminal A subtype. ( Alramadhan, M; Bae, SY; Kim, SW; Lee, JE; Lee, SK; Nam, SJ; Paik, HJ; Park, S; Rayzah, M; Ryu, JM; Yu, J, 2016) |
| "Capecitabine is an oral fluoropyrimidine derivative which is frequently used alone or in combination regimens for the treatment of metastatic breast cancer." | 7.80 | Lack of prognostic value of mean corpuscular volume with capecitabine therapy in metastatic breast cancer. ( Berk, V; Bozkurt, O; Cetin, B; Duran, AO; Inanc, M; Kaplan, MA; Karaca, H; Ozaslan, E; Ozkan, M, 2014) |
| "This study evaluated whether doxorubicin and cyclophosphamide are superior to cyclophosphamide, methotrexate and 5-fluorouracil as adjuvant chemotherapy in breast cancer patients." | 7.75 | Doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil as adjuvant chemotherapy in breast cancer. ( Bianchi, S; Biti, GP; Borghesi, S; Cataliotti, L; De Luca Cardillo, C; Greto, D; Livi, L; Mangoni, M; Paiar, F; Saieva, C; Scotti, V, 2009) |
| "Weekly paclitaxel plus capecitabine is a safety and active chemotherapy in previously treated metastatic breast cancer." | 7.73 | Weekly paclitaxel plus capecitabine in advanced breast cancer patients: dose-finding trial of GOIRC and GOL. ( Bilancia, D; Cognetti, F; Di Costanzo, F; Gasperoni, S; Landucci, E; Manzione, L; Mazzoni, F; Papaldo, P, 2006) |
| "The aim of this study was to evaluate the efficacy and safety of neoadjuvant chemotherapy with infusional 5-fluorouracil (5-FU), adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer (LABC)." | 7.73 | Neoadjuvant chemotherapy with infusional 5-fluorouracil, adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer: an early response predicts good prognosis. ( Chung, HC; Jeung, HC; Moon, YW; Rha, SY; Suh, CO; Yang, WI, 2005) |
| "Among breast cancer patients, nonresponse to initial neoadjuvant chemotherapy is associated with unfavorable outcome." | 6.73 | Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. ( Costa, SD; Eidtmann, H; Gerber, B; Hanusch, C; Hilfrich, J; Huober, J; Jackisch, C; Kaufmann, M; Kümmel, S; Loibl, S; Mehta, K; Vogel, P; von Minckwitz, G, 2008) |
| "From January 2003 to March 2005, five breast cancer patients with brain metastases were referred for WBRT with concurrent capecitabine." | 5.35 | Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients. ( Campana, F; Castro Pena, P; Chargari, C; Cottu, PH; Diéras, V; Fourquet, A; Kirova, YM; Pena, PC; Pierga, J, 2009) |
| " Women aged 65-79, operated for breast cancer, with average to high risk of recurrence, were allocated 1 : 1 to CMF (cyclophosphamide 600 mg/m², methotrexate 40 mg/m², fluorouracil 600 mg/m², days 1, 8) or docetaxel (35 mg/m(2) days 1, 8, 15) every 4 weeks, for four or six cycles according to hormone receptor status." | 5.20 | Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. ( Barni, S; Botti, G; Colantuoni, G; D'Aiuto, M; Daniele, B; Daniele, G; De Laurentiis, M; De Maio, E; de Matteis, A; De Placido, S; Di Maio, M; Di Rella, F; Forestieri, V; Gallo, C; Gori, S; Gravina, A; Iodice, G; Labonia, V; Landi, G; Lauria, R; Montanino, A; Morabito, A; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Riccardi, F; Rossi, E; Signoriello, S; Tinessa, V, 2015) |
| "To determine rates of pathologic complete response (pCR) and near-complete response (npCR) in operable early-stage breast cancer using neoadjuvant capecitabine plus docetaxel, with or without trastuzumab, and investigate biomarkers of pathologic response." | 5.16 | TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab. ( Avisar, E; Glück, S; McKenna, EF; Perou, CM; Ross, JS; Royce, M; Wu, L, 2012) |
| "Women with axillary node-positive or high-risk node-negative breast cancer were randomly assigned to receive either three cycles of docetaxel and capecitabine (TX) followed by three cycles of cyclophosphamide, epirubicin, and capecitabine (CEX; n = 753) or three cycles of docetaxel (T) followed by three cycles of cyclophosphamide, epirubicin, and fluorouracil (CEF; n = 747)." | 5.16 | Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. ( Ahlgren, J; Asola, R; Auvinen, P; Bono, P; Helle, L; Huovinen, R; Joensuu, H; Jukkola-Vuorinen, A; Kataja, V; Kellokumpu-Lehtinen, PL; Kokko, R; Leinonen, M; Lindman, H; Nilsson, G; Nyandoto, P; Paija, O; Pajunen, M; Poikonen, P; Tanner, M; Villman, K, 2012) |
| "After breast cancer surgery, women with lymph node-positive disease were randomly assigned to treatment with fluorouracil, epirubicin, and cyclophosphamide (FEC) or with FEC followed by weekly paclitaxel (FEC-P)." | 5.13 | Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. ( Adrover, E; Alba, E; Almenar, S; Alvarez, I; Alvarez, JV; Antón, A; Aranda, E; Baena, JM; Calvo, L; Crespo, C; de Alava, E; García Puche, JL; Gonzalez, S; González-Palacios, JF; Gracia Marco, JM; Guitián, MD; Lluch, A; López García-Asenjo, JA; López-Vega, JM; Martín, M; Mayordomo, JI; Mel, JR; Modolell, A; Munárriz, B; Palacios, J; Pelegrí, A; Plazaola, A; Ramos, M; Rodríguez, CA; Rodríguez-Lescure, A; Ruiz, A; Ruiz-Borrego, M; Sánchez-Rovira, P; Seguí, MA; Vera, F, 2008) |
| "To evaluate tolerance and toxicity of high-dose epirubicin regimen CEF-100 as adjuvant therapy for breast cancer." | 5.12 | [Comparison of tolerance and toxicity of CEF-100 regimen versus CEF-60 regimen as adjuvant therapy for breast cancer]. ( Hao, XM; Hui, R; Zhang, J; Zhang, M, 2007) |
| "The purpose was to compare disease-free survival (DFS) between epirubicin-based chemoendocrine therapy and tamoxifen alone in one to three node-positive (N1-3), estrogen-receptor-positive (ER+), postmenopausal early breast cancer (EBC) patients." | 5.12 | Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 ( Bonneterre, J; Campone, M; Fargeot, P; Kerbrat, P; Luporsi, E; Monnier, A; Montcuquet, P; Namer, M; Roché, H; Romestaing, P, 2006) |
| " A total of 283 women with metastatic breast cancer were initially enrolled in a randomised multicentre trial comparing docetaxel to sequential methotrexate-fluorouracil (MF) in advanced breast cancer after anthracycline failure." | 5.11 | Cyclin A as a marker for prognosis and chemotherapy response in advanced breast cancer. ( Ahlgren, J; Amini, RM; Blomqvist, C; Poikonen, P; Sjöström, J; Villman, K, 2005) |
| "Within 7 years 263 women with stage II breast cancer were randomised either to receive 1 cycle of doxorubicin, vinblastine, cyclophosphamide, methotrexate and 5- fluorouracil (AV-CMF) or to receive 6 cycles of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)." | 5.10 | Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients. ( Fridrik, M; Gnant, M; Haider, K; Hausmaninger, H; Jakesz, R; Kolb, R; Kubista, E; Mlineritsch, B; Ploner, F; Samonigg, H; Seifert, M; Steger, G; Steindorfer, P; Stierer, M; Tschurtschenthaler, G, 2003) |
| "Phase II study evaluating efficacy and safety of combined oxaliplatin/fluorouracil (5-FU) in taxane-pretreated advanced and metastatic breast cancer (ABC) patients." | 5.10 | Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients. ( Chollet, P; Chouaki, N; Cottu, P; Culine, S; Dieras, V; Gamelin, E; Mackenzie, S; Marty, M; Misset, JL; Spielmann, M; Tubiana-Hulin, M; Vannetzel, JM; Zelek, L, 2002) |
| "To study the outcomes of adjuvant goserelin combined with tamoxifen (GosTam) compared to chemotherapy followed by tamoxifen (ChemTam) in premenopausal patients with early stage, luminal A breast cancer." | 3.83 | Goserelin plus tamoxifen compared to chemotherapy followed by tamoxifen in premenopausal patients with early stage-, lymph node-negative breast cancer of luminal A subtype. ( Alramadhan, M; Bae, SY; Kim, SW; Lee, JE; Lee, SK; Nam, SJ; Paik, HJ; Park, S; Rayzah, M; Ryu, JM; Yu, J, 2016) |
| "Capecitabine is an oral fluoropyrimidine derivative which is frequently used alone or in combination regimens for the treatment of metastatic breast cancer." | 3.80 | Lack of prognostic value of mean corpuscular volume with capecitabine therapy in metastatic breast cancer. ( Berk, V; Bozkurt, O; Cetin, B; Duran, AO; Inanc, M; Kaplan, MA; Karaca, H; Ozaslan, E; Ozkan, M, 2014) |
| "Forty-three patients with 45 breast cancers were treated with neoadjuvant docetaxel-epirubicin with/without capecitabine chemotherapy." | 3.77 | Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer. ( Brodowicz, T; Csörgo, E; Kahán, Z; Kaizer, L; Lázár, G; Nikolényi, A; Ormándi, K; Sükösd, F; Thurzó, L; Uhercsák, G; Vörös, A, 2011) |
| "This study evaluated whether doxorubicin and cyclophosphamide are superior to cyclophosphamide, methotrexate and 5-fluorouracil as adjuvant chemotherapy in breast cancer patients." | 3.75 | Doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil as adjuvant chemotherapy in breast cancer. ( Bianchi, S; Biti, GP; Borghesi, S; Cataliotti, L; De Luca Cardillo, C; Greto, D; Livi, L; Mangoni, M; Paiar, F; Saieva, C; Scotti, V, 2009) |
| "The aim of this study was to evaluate the efficacy and safety of neoadjuvant chemotherapy with infusional 5-fluorouracil (5-FU), adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer (LABC)." | 3.73 | Neoadjuvant chemotherapy with infusional 5-fluorouracil, adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer: an early response predicts good prognosis. ( Chung, HC; Jeung, HC; Moon, YW; Rha, SY; Suh, CO; Yang, WI, 2005) |
| "Weekly paclitaxel plus capecitabine is a safety and active chemotherapy in previously treated metastatic breast cancer." | 3.73 | Weekly paclitaxel plus capecitabine in advanced breast cancer patients: dose-finding trial of GOIRC and GOL. ( Bilancia, D; Cognetti, F; Di Costanzo, F; Gasperoni, S; Landucci, E; Manzione, L; Mazzoni, F; Papaldo, P, 2006) |
| "We report a breast cancer patient who developed acute myeloid leukemia (AML) one year following her adjuvant chemotherapy consisting of cyclophosphamide, adriamycin and 5-fluorouracil." | 3.73 | t(8;16) AML developed subsequent to breast cancer therapy. ( Akçali, Z; Boğa, S; DemIrhan, B; Karakuş, S; Sahin, FI; Yilmaz, Z, 2006) |
| "The frequencies of chromosomal aberrations (CAs) and sister chromatid exchanges (SCEs) were determined in peripheral blood lymphocyte cultures from women with breast cancer treated by chemotherapy (CT) with FEC (5-fluorouracil, epirubicin, and cyclophosphamide) or CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) cocktail in six CT cycles." | 3.71 | Study of chromosome damage in patients with breast cancer treated by two antineoplastic treatments. ( Carrara, HH; Silva, LM; Takahashi, CS, 2002) |
| "Gemcitabine and capecitabine are nucleoside analogues used in chemotherapy strategies for the treatment of breast cancer." | 3.71 | Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. ( Baldwin, SA; Cass, CE; Clarke, ML; Coupland, RW; Dabbagh, L; Jennings, LL; Koski, SL; Mackey, JR; Santos, CL; Vsianska, M; Young, JD, 2002) |
| "Between 1975 and 1986, 326 patients with stage II breast cancer were treated with an adjuvant combination of doxorubicin, vincristine, cyclophosphamide, and 5-fluorouracil (AVCF) following regional therapy (232 modified radical mastectomy, 94 lumpectomies, 304 irradiations)." | 3.69 | Adjuvant chemotherapy with doxorubicin-containing regimen for 326 stage II breast cancers: 15-year results. ( Achard, JL; Bélembaogo, E; Charrier, S; Chollet, P; Courtadon, M; Curé, H; Dauplat, J; de Latour, M; Ferrière, JP; Kwiatkowski, F, 1997) |
| "Given the proven prognostic value of circulating tumor cells (CTCs) in EBC, we compared the prevalence of CTCs after chemotherapy between both treatment arms for a preliminary efficacy assessment." | 2.84 | Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer. ( Alunni-Fabbroni, M; Andergassen, U; Camara, O; de Gregorio, N; Decker, T; Fasching, PA; Fehm, TN; Friedl, TWP; Heinrich, G; Jaeger, B; Janni, W; Mahner, S; Ober, A; Pantel, K; Rack, BK; Schneeweiss, A; Schochter, F; Schramm, A; Trapp, E, 2017) |
| "Adjuvant trastuzumab in combination with chemotherapy improves survival of women with HER2-positive early breast cancer." | 2.80 | Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). ( Boukovinas, I; Georgoulias, V; Kakolyris, S; Kentepozidis, N; Malamos, N; Mavroudis, D; Papakotoulas, P; Saloustros, E; Ziras, N, 2015) |
| "Patients with node-positive early breast cancer were randomly assigned 1:1 to two different dose-dense chemotherapy regimens and 2:1 to ibandronate 50 mg per day orally for 2 years or observation." | 2.78 | German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. ( Barinoff, J; Bauerfeind, I; Belau, A; Clemens, M; Conrad, B; Diel, IJ; Elling, D; Forstbauer, H; Harbeck, N; Huober, J; Jackisch, C; Kreienberg, R; Loibl, S; Lück, HJ; Möbus, V; Müller, V; Nekljudova, V; Noeding, S; Schmidt, M; Schneeweiss, A; Thomssen, C; Untch, M; von Minckwitz, G, 2013) |
| "MAI (≥ 10) was strongly associated with breast cancer-related death in lymph node (LN)-negative patients (hazard ratio (HR): 7." | 2.76 | Mitotic activity and bone marrow micrometastases have independent prognostic value in node positive breast cancer patients. ( Baak, JP; Gilje, B; Janssen, EA; Nordgård, O; Smaaland, R; Søiland, H; Tjensvoll, K, 2011) |
| "Among breast cancer patients, nonresponse to initial neoadjuvant chemotherapy is associated with unfavorable outcome." | 2.73 | Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. ( Costa, SD; Eidtmann, H; Gerber, B; Hanusch, C; Hilfrich, J; Huober, J; Jackisch, C; Kaufmann, M; Kümmel, S; Loibl, S; Mehta, K; Vogel, P; von Minckwitz, G, 2008) |
| "A patient with recurrent breast cancer, who was diagnosed with eyelid metastasis as a part of systemic metastases and in whom systemic chemotherapy was markedly effective, is reported." | 2.39 | Eyelid metastasis from breast cancer showing marked response to chemotherapy. ( Abe, K; Adachi, I; Kaneko, A; Narabayashi, M; Tokue, Y; Tsuda, H; Watanabe, T; Yin, DF; Zhang, GJ, 1995) |
| "Lobular carcinoma is a very uncommon histopathologic form of male breast cancer because of the absence of lobules in the normal male breast." | 2.39 | Lobular carcinoma of the male breast. ( Michaels, BM; Nunn, CR; Roses, DF, 1994) |
| "Breast tumors were dichotomized into round + oval and irregular types based on MRI morphology." | 1.42 | Prediction of pathological complete response to neoadjuvant chemotherapy by magnetic resonance imaging in breast cancer patients. ( Kagara, N; Kim, SJ; Maruyama, N; Michishita, S; Naoi, Y; Noguchi, S; Shimazu, K; Shimoda, M; Shimomura, A; Sota, Y, 2015) |
| "One hundred and forty-nine breast cancer patients eligible for neoadjuvant chemotherapy were included in the study between February 2004 and January 2009 at three centers." | 1.39 | Plasma and tissue proteomic prognostic factors of response in primary breast cancer patients receiving neoadjuvant chemotherapy. ( Blot, E; Bonneterre, J; Desauw, C; Fournier, C; Hornez, L; Kramar, A; Peyrat, JP; Révillion, F, 2013) |
| "The triple negative breast cancer (TNBC) was most sensitive to chemotherapy with 19% achieving clinical-complete-response (cCR) followed by HER2 enriched (2/22 (9%) cCR), luminal B (1/6 (7%) cCR) and luminal A (0/10 (0%) cCR)." | 1.39 | Association of immunohistochemically defined molecular subtypes with clinical response to presurgical chemotherapy in patients with advanced breast cancer. ( Khokher, S; Mahmood, S; Nagi, AH; Qureshi, MU, 2013) |
| "Among the low and intermediate grade breast cancers, the FGFR1 negative tumors were resistant to chemoradiotherapy." | 1.38 | The fibroblast growth factor receptor 1 (FGFR1), a marker of response to chemoradiotherapy in breast cancer? ( Belin, L; Cohen-Jonathan-Moyal, E; Fourquet, A; Hall, J; Kirova, YM; Massabeau, C; Mégnin-Chanet, F; Richardson, M; Savignoni, A; Sigal-Zafrani, B, 2012) |
| "Forty percent of patients with TN breast cancer recurred after a median follow-up of nearly 11 years, but only 22% of those achieving a pCR." | 1.38 | Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer. ( Alran, S; Beuzeboc, P; Dettwiler, S; Diéras, V; Fréneaux, P; Laurence, V; Le Tourneau, C; Pierga, JY; Sigal-Zafrani, B; Vincent-Salomon, A, 2012) |
| "Locoregional treatment of inflammatory breast cancer (IBC) is crucial because local relapses may be highly symptomatic and are commonly associated with distant metastasis." | 1.38 | Exclusive alternating chemotherapy and radiotherapy in nonmetastatic inflammatory breast cancer: 20 years of follow-up. ( Arriagada, R; Bourgier, C; Dunant, A; Heymann, S; Marsiglia, H; Mathieu, MC; Pessoa, EL; Spielmann, M; Uzan, C, 2012) |
| "Sixty five patients with breast cancer underwent (99)Tc(m)-MIBI scintimammography before NCT, and static planar images were taken at 10 min and 180 min after scintimammography." | 1.37 | [Predictive value of (99)Tc(m)-MIBI scintimammography in evaluation of the efficacy of neoadjuvant chemotherapy in patients with operable breast cancer]. ( Cui, SD; Li, LF; Li, WL; Liu, H; Liu, ZZ; Lu, ZD; Yang, H; Zhang, HW, 2011) |
| "One hundred and fourteen cases of breast cancer with NA therapy were analyzed and clinical data were collected from March 2007 to December 2010." | 1.37 | [Primary systemic therapy in breast cancer patients (2007-2010)]. ( Farkas, R; Horváth, OP; Kálmán, E; Kovács, G; Kövér, E; Pavlovics, G; Szalai, G; Tizedes, G; Zapf, I, 2011) |
| "From January 2003 to March 2005, five breast cancer patients with brain metastases were referred for WBRT with concurrent capecitabine." | 1.35 | Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients. ( Campana, F; Castro Pena, P; Chargari, C; Cottu, PH; Diéras, V; Fourquet, A; Kirova, YM; Pena, PC; Pierga, J, 2009) |
| "This is the first study investigating neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with chemotherapy in patients with breast cancer." | 1.33 | Neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with systemic chemotherapy in patients with breast cancer. ( Baltas, D; Filipowicz, I; Hoffmann, G; Kolotas, C; Kontova, M; Kuner, RP; Kurek, R; Martin, T; Pollow, B; Roddiger, SJ; Rogge, B; Zamboglou, N, 2006) |
| "From 59 breast cancer patients treated with neoadjuvant chemotherapy and 33 without neoadjuvant therapy (control), core biopsy samples before the chemotherapy or surgery and surgical specimens were obtained for assay of ER, PR, and HER-2 expression." | 1.32 | [Effects of neoadjuvant chemotherapy on estrogen and progesterone receptors and HER-2 in breast cancer]. ( Wang, J; Wang, YD; Wu, YL; Zhao, GR; Zhao, J, 2004) |
| "We found that the hazard function of metastasis in time presented two peaks of incidence at 20 and 60 months, respectively." | 1.31 | Angiogenesis sustains tumor dormancy in patients with breast cancer treated with adjuvant chemotherapy. ( Biganzoli, E; Bonoldi, E; Boracchi, P; Fanelli, M; Gasparini, G; Morabito, A, 2001) |
| "Thirteen (23%) of 56 women had no residual tumor." | 1.29 | Locally advanced breast carcinoma: accuracy of mammography versus clinical examination in the prediction of residual disease after chemotherapy. ( Adler, DD; Cody, RL; Helvie, MA; Joynt, LK; Merajver, SD; Pierce, LJ, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (12.82) | 18.2507 |
| 2000's | 32 (41.03) | 29.6817 |
| 2010's | 34 (43.59) | 24.3611 |
| 2020's | 2 (2.56) | 2.80 |
| Authors | Studies |
|---|---|
| de Boo, L | 1 |
| Cimino-Mathews, A | 1 |
| Lubeck, Y | 1 |
| Daletzakis, A | 1 |
| Opdam, M | 1 |
| Sanders, J | 1 |
| Hooijberg, E | 1 |
| van Rossum, A | 1 |
| Loncova, Z | 1 |
| Rieder, D | 1 |
| Trajanoski, Z | 1 |
| Vollebergh, M | 1 |
| Sobral-Leite, M | 1 |
| van de Vijver, K | 1 |
| Broeks, A | 1 |
| van der Wiel, R | 1 |
| van Tinteren, H | 1 |
| Linn, S | 1 |
| Horlings, HM | 1 |
| Kok, M | 1 |
| Ishiguro, H | 1 |
| Masuda, N | 1 |
| Sato, N | 1 |
| Higaki, K | 1 |
| Morimoto, T | 1 |
| Yanagita, Y | 1 |
| Mizutani, M | 1 |
| Ohtani, S | 1 |
| Kaneko, K | 1 |
| Fujisawa, T | 1 |
| Takahashi, M | 1 |
| Kadoya, T | 1 |
| Matsunami, N | 1 |
| Yamamoto, Y | 1 |
| Ohno, S | 1 |
| Takano, T | 1 |
| Morita, S | 1 |
| Tanaka-Mizuno, S | 1 |
| Toi, M | 1 |
| Khokher, S | 1 |
| Qureshi, MU | 1 |
| Mahmood, S | 1 |
| Nagi, AH | 1 |
| von Minckwitz, G | 3 |
| Möbus, V | 1 |
| Schneeweiss, A | 2 |
| Huober, J | 2 |
| Thomssen, C | 1 |
| Untch, M | 2 |
| Jackisch, C | 2 |
| Diel, IJ | 1 |
| Elling, D | 1 |
| Conrad, B | 1 |
| Kreienberg, R | 1 |
| Müller, V | 1 |
| Lück, HJ | 1 |
| Bauerfeind, I | 1 |
| Clemens, M | 1 |
| Schmidt, M | 1 |
| Noeding, S | 1 |
| Forstbauer, H | 1 |
| Barinoff, J | 1 |
| Belau, A | 1 |
| Nekljudova, V | 1 |
| Harbeck, N | 2 |
| Loibl, S | 3 |
| Mazouni, C | 2 |
| Naveau, A | 1 |
| Kane, A | 1 |
| Dunant, A | 2 |
| Garbay, JR | 1 |
| Leymarie, N | 1 |
| Sarfati, B | 1 |
| Delaloge, S | 1 |
| Rimareix, F | 1 |
| Lamberth, F | 1 |
| Guilbert, P | 1 |
| Gaillot-Petit, N | 1 |
| Champagne, C | 1 |
| Looten-Vieren, L | 1 |
| Nguyen, TD | 1 |
| Noda, S | 2 |
| Kashiwagi, S | 2 |
| Kawajiri, H | 2 |
| Takashima, T | 2 |
| Onoda, N | 2 |
| Hirakawa, K | 2 |
| Bozkurt, O | 1 |
| Berk, V | 1 |
| Kaplan, MA | 1 |
| Cetin, B | 1 |
| Ozaslan, E | 1 |
| Karaca, H | 1 |
| Inanc, M | 1 |
| Duran, AO | 1 |
| Ozkan, M | 1 |
| Bozovic-Spasojevic, I | 1 |
| Ameye, L | 1 |
| Paesmans, M | 1 |
| Larsimont, D | 1 |
| Di Leo, A | 1 |
| Dolci, S | 1 |
| Piccart, M | 1 |
| de Azambuja, E | 1 |
| Loi, S | 1 |
| Narui, K | 1 |
| Ishikawa, T | 2 |
| Satake, T | 1 |
| Adachi, S | 1 |
| Yamada, A | 1 |
| Shimada, K | 1 |
| Shimizu, D | 1 |
| Kida, K | 1 |
| Sugae, S | 1 |
| Ichikawa, Y | 1 |
| Tanabe, M | 1 |
| Sasaki, T | 1 |
| Endo, I | 1 |
| Perrone, F | 1 |
| Nuzzo, F | 1 |
| Di Rella, F | 1 |
| Gravina, A | 1 |
| Iodice, G | 1 |
| Labonia, V | 1 |
| Landi, G | 1 |
| Pacilio, C | 1 |
| Rossi, E | 1 |
| De Laurentiis, M | 1 |
| D'Aiuto, M | 1 |
| Botti, G | 1 |
| Forestieri, V | 1 |
| Lauria, R | 1 |
| De Placido, S | 1 |
| Tinessa, V | 1 |
| Daniele, B | 1 |
| Gori, S | 1 |
| Colantuoni, G | 1 |
| Barni, S | 1 |
| Riccardi, F | 1 |
| De Maio, E | 1 |
| Montanino, A | 1 |
| Morabito, A | 2 |
| Daniele, G | 1 |
| Di Maio, M | 1 |
| Piccirillo, MC | 1 |
| Signoriello, S | 1 |
| Gallo, C | 1 |
| de Matteis, A | 1 |
| Michishita, S | 1 |
| Kim, SJ | 1 |
| Shimazu, K | 1 |
| Sota, Y | 1 |
| Naoi, Y | 1 |
| Maruyama, N | 1 |
| Kagara, N | 1 |
| Shimoda, M | 1 |
| Shimomura, A | 1 |
| Noguchi, S | 1 |
| Mavroudis, D | 1 |
| Saloustros, E | 1 |
| Malamos, N | 1 |
| Kakolyris, S | 1 |
| Boukovinas, I | 1 |
| Papakotoulas, P | 1 |
| Kentepozidis, N | 1 |
| Ziras, N | 1 |
| Georgoulias, V | 1 |
| Gonçalves, A | 1 |
| Pierga, JY | 2 |
| Ferrero, JM | 1 |
| Mouret-Reynier, MA | 1 |
| Bachelot, T | 1 |
| Delva, R | 1 |
| Fabbro, M | 1 |
| Lerebours, F | 1 |
| Lotz, JP | 1 |
| Linassier, C | 1 |
| Dohollou, N | 1 |
| Eymard, JC | 1 |
| Leduc, B | 1 |
| Lemonnier, J | 1 |
| Martin, AL | 1 |
| Boher, JM | 1 |
| Viens, P | 1 |
| Roché, H | 2 |
| de Oliveira, SF | 1 |
| Ganzinelli, M | 1 |
| Chilà, R | 1 |
| Serino, L | 1 |
| Maciel, ME | 1 |
| Urban, Cde A | 1 |
| de Lima, RS | 1 |
| Cavalli, IJ | 1 |
| Generali, D | 1 |
| Broggini, M | 1 |
| Damia, G | 1 |
| Ribeiro, EM | 1 |
| Redana, S | 1 |
| Sharp, A | 1 |
| Lote, H | 1 |
| Mohammed, K | 1 |
| Papadimitraki, E | 1 |
| Capelan, M | 1 |
| Ring, A | 1 |
| Alramadhan, M | 1 |
| Ryu, JM | 1 |
| Rayzah, M | 1 |
| Nam, SJ | 1 |
| Kim, SW | 1 |
| Yu, J | 1 |
| Lee, SK | 1 |
| Bae, SY | 1 |
| Park, S | 1 |
| Paik, HJ | 1 |
| Lee, JE | 1 |
| Ma, Y | 1 |
| Zhang, S | 1 |
| Zang, L | 1 |
| Li, J | 2 |
| Kang, Y | 1 |
| Ren, W | 1 |
| Schramm, A | 1 |
| Schochter, F | 1 |
| Friedl, TWP | 1 |
| de Gregorio, N | 1 |
| Andergassen, U | 1 |
| Alunni-Fabbroni, M | 1 |
| Trapp, E | 1 |
| Jaeger, B | 1 |
| Heinrich, G | 2 |
| Camara, O | 1 |
| Decker, T | 1 |
| Ober, A | 1 |
| Mahner, S | 1 |
| Fehm, TN | 1 |
| Pantel, K | 1 |
| Fasching, PA | 1 |
| Janni, W | 1 |
| Rack, BK | 1 |
| Chargari, C | 1 |
| Kirova, YM | 2 |
| Diéras, V | 3 |
| Castro Pena, P | 1 |
| Pena, PC | 1 |
| Campana, F | 1 |
| Cottu, PH | 1 |
| Pierga, J | 1 |
| Fourquet, A | 2 |
| Dubois, N | 1 |
| Willems, T | 1 |
| Myant, N | 1 |
| Boidot, R | 1 |
| Vegran, F | 1 |
| Soubeyrand, MS | 1 |
| Fumoleau, P | 1 |
| Coudert, B | 1 |
| Lizard-Nacol, S | 1 |
| Manga, GP | 1 |
| Shahi, PK | 1 |
| Ureña, MM | 1 |
| Pereira, RQ | 1 |
| Plaza, MI | 1 |
| Peron, YI | 1 |
| Val, RG | 1 |
| Carrión, JB | 1 |
| Cañón, EP | 1 |
| Alfonso, PG | 1 |
| Livi, L | 1 |
| Saieva, C | 1 |
| Borghesi, S | 1 |
| De Luca Cardillo, C | 1 |
| Scotti, V | 1 |
| Mangoni, M | 1 |
| Greto, D | 1 |
| Cataliotti, L | 1 |
| Paiar, F | 1 |
| Bianchi, S | 1 |
| Biti, GP | 1 |
| Jung, M | 1 |
| Shin, HJ | 1 |
| Rha, SY | 2 |
| Jeung, HC | 2 |
| Hong, S | 1 |
| Moon, YW | 2 |
| Kim, HS | 1 |
| Oh, KJ | 1 |
| Yang, WI | 2 |
| Roh, JK | 1 |
| Chung, HC | 2 |
| Noske, A | 1 |
| Darb-Esfahani, S | 1 |
| Roller, M | 1 |
| Kronenwett, R | 1 |
| Müller, BM | 1 |
| Steffen, J | 1 |
| von Toerne, C | 1 |
| Wirtz, R | 1 |
| Baumann, I | 1 |
| Hoffmann, G | 2 |
| Grasshoff, ST | 1 |
| Ulmer, HU | 1 |
| Denkert, C | 1 |
| Nakata, B | 1 |
| Kato, Y | 1 |
| Bourgier, C | 1 |
| Pessoa, EL | 1 |
| Heymann, S | 1 |
| Spielmann, M | 2 |
| Uzan, C | 1 |
| Mathieu, MC | 1 |
| Arriagada, R | 1 |
| Marsiglia, H | 1 |
| Le Tourneau, C | 1 |
| Dettwiler, S | 1 |
| Beuzeboc, P | 1 |
| Alran, S | 1 |
| Laurence, V | 1 |
| Fréneaux, P | 1 |
| Sigal-Zafrani, B | 2 |
| Vincent-Salomon, A | 1 |
| Glück, S | 1 |
| Ross, JS | 1 |
| Royce, M | 1 |
| McKenna, EF | 1 |
| Perou, CM | 1 |
| Avisar, E | 1 |
| Wu, L | 1 |
| Gilje, B | 1 |
| Nordgård, O | 1 |
| Tjensvoll, K | 1 |
| Janssen, EA | 1 |
| Søiland, H | 1 |
| Smaaland, R | 1 |
| Baak, JP | 1 |
| Delpeuch, A | 1 |
| Leveque, D | 1 |
| Rob, L | 1 |
| Bergerat, JP | 1 |
| Liem, X | 1 |
| Baranzelli, MC | 1 |
| Penel, N | 1 |
| Giard, S | 1 |
| Bonneterre, J | 3 |
| Nikolényi, A | 1 |
| Sükösd, F | 1 |
| Kaizer, L | 1 |
| Csörgo, E | 1 |
| Vörös, A | 1 |
| Uhercsák, G | 1 |
| Ormándi, K | 1 |
| Lázár, G | 1 |
| Thurzó, L | 1 |
| Brodowicz, T | 1 |
| Kahán, Z | 1 |
| Zapf, I | 1 |
| Tizedes, G | 1 |
| Pavlovics, G | 1 |
| Kovács, G | 1 |
| Kálmán, E | 1 |
| Szalai, G | 1 |
| Kövér, E | 1 |
| Farkas, R | 1 |
| Horváth, OP | 1 |
| Liu, ZZ | 1 |
| Lu, ZD | 1 |
| Zhang, HW | 1 |
| Yang, H | 1 |
| Liu, H | 1 |
| Li, LF | 1 |
| Li, WL | 1 |
| Cui, SD | 1 |
| Joensuu, H | 1 |
| Kellokumpu-Lehtinen, PL | 1 |
| Huovinen, R | 1 |
| Jukkola-Vuorinen, A | 1 |
| Tanner, M | 1 |
| Kokko, R | 1 |
| Ahlgren, J | 2 |
| Auvinen, P | 1 |
| Paija, O | 1 |
| Helle, L | 1 |
| Villman, K | 2 |
| Nyandoto, P | 1 |
| Nilsson, G | 1 |
| Pajunen, M | 1 |
| Asola, R | 1 |
| Poikonen, P | 2 |
| Leinonen, M | 1 |
| Kataja, V | 1 |
| Bono, P | 1 |
| Lindman, H | 1 |
| Karasawa, K | 1 |
| Saito, M | 1 |
| Hirowatari, H | 1 |
| Izawa, H | 1 |
| Furuya, T | 1 |
| Ozawa, S | 1 |
| Ito, K | 1 |
| Suzuki, T | 1 |
| Mitsuhashi, N | 1 |
| Massabeau, C | 1 |
| Belin, L | 1 |
| Savignoni, A | 1 |
| Richardson, M | 1 |
| Cohen-Jonathan-Moyal, E | 1 |
| Mégnin-Chanet, F | 1 |
| Hall, J | 1 |
| Révillion, F | 1 |
| Desauw, C | 1 |
| Blot, E | 1 |
| Kramar, A | 1 |
| Fournier, C | 1 |
| Hornez, L | 1 |
| Peyrat, JP | 1 |
| Silva, LM | 1 |
| Takahashi, CS | 1 |
| Carrara, HH | 1 |
| Parton, M | 1 |
| Krajewski, S | 1 |
| Smith, I | 1 |
| Krajewska, M | 1 |
| Archer, C | 1 |
| Naito, M | 1 |
| Ahern, R | 1 |
| Reed, J | 1 |
| Dowsett, M | 1 |
| Cocquyt, VF | 1 |
| Blondeel, PN | 1 |
| Depypere, HT | 1 |
| Praet, MM | 1 |
| Schelfhout, VR | 1 |
| Silva, OE | 1 |
| Hurley, J | 1 |
| Serreyn, RF | 1 |
| Daems, KK | 1 |
| Van Belle, SJ | 1 |
| Ploner, F | 1 |
| Jakesz, R | 1 |
| Hausmaninger, H | 1 |
| Kolb, R | 1 |
| Stierer, M | 1 |
| Fridrik, M | 1 |
| Steindorfer, P | 1 |
| Gnant, M | 1 |
| Haider, K | 1 |
| Mlineritsch, B | 1 |
| Tschurtschenthaler, G | 1 |
| Steger, G | 1 |
| Seifert, M | 1 |
| Kubista, E | 1 |
| Samonigg, H | 1 |
| Tamaru, N | 1 |
| Hishikawa, Y | 1 |
| Ejima, K | 1 |
| Nagasue, N | 1 |
| Inoue, S | 1 |
| Muramatsu, M | 1 |
| Hayashi, T | 1 |
| Koji, T | 1 |
| Zhao, J | 1 |
| Wu, YL | 1 |
| Wang, YD | 1 |
| Zhao, GR | 1 |
| Wang, J | 1 |
| Brunello, A | 1 |
| Basso, U | 1 |
| Pogliani, C | 1 |
| Jirillo, A | 1 |
| Ghiotto, C | 1 |
| Koussis, H | 1 |
| Lumachi, F | 1 |
| Iacobone, M | 1 |
| Vamvakas, L | 1 |
| Monfardini, S | 1 |
| Suh, CO | 1 |
| Sjöström, J | 1 |
| Amini, RM | 1 |
| Blomqvist, C | 1 |
| Di Costanzo, F | 1 |
| Gasperoni, S | 1 |
| Papaldo, P | 1 |
| Bilancia, D | 1 |
| Manzione, L | 1 |
| Landucci, E | 1 |
| Mazzoni, F | 1 |
| Cognetti, F | 1 |
| Altinyollar, H | 1 |
| Dingil, G | 1 |
| Berberoglu, U | 1 |
| Namer, M | 1 |
| Fargeot, P | 1 |
| Campone, M | 1 |
| Kerbrat, P | 1 |
| Romestaing, P | 1 |
| Monnier, A | 1 |
| Luporsi, E | 1 |
| Montcuquet, P | 1 |
| Roddiger, SJ | 1 |
| Kolotas, C | 1 |
| Filipowicz, I | 1 |
| Kurek, R | 1 |
| Kuner, RP | 1 |
| Martin, T | 1 |
| Baltas, D | 1 |
| Rogge, B | 1 |
| Kontova, M | 1 |
| Pollow, B | 1 |
| Zamboglou, N | 1 |
| Resnik, KS | 1 |
| DiLeonardo, M | 1 |
| Gibbons, G | 1 |
| Hall, A | 1 |
| Broglio, K | 1 |
| Fritsche, H | 1 |
| Andre, F | 1 |
| Esteva, FJ | 1 |
| Hortobagyi, GN | 2 |
| Buzdar, AU | 2 |
| Pusztai, L | 1 |
| Cristofanilli, M | 1 |
| Sahin, FI | 1 |
| Yilmaz, Z | 1 |
| Karakuş, S | 1 |
| Boğa, S | 1 |
| Akçali, Z | 1 |
| DemIrhan, B | 1 |
| Shen, J | 1 |
| Gilcrease, MZ | 1 |
| Babiera, GV | 1 |
| Ross, MI | 1 |
| Meric-Bernstam, F | 1 |
| Feig, BW | 1 |
| Kuerer, HM | 1 |
| Francis, A | 1 |
| Ames, FC | 1 |
| Hunt, KK | 1 |
| Genet, D | 1 |
| Lejeune, C | 1 |
| Bonnier, P | 1 |
| Aubard, Y | 1 |
| Venat-Bouvet, L | 1 |
| Adjadj, DJ | 1 |
| Martin, J | 1 |
| Labourey, JL | 1 |
| Benyoub, A | 1 |
| Clavère, P | 1 |
| Lebrun-Ly, V | 1 |
| Juin, P | 1 |
| Piana, L | 1 |
| Tubiana-Mathieu, N | 1 |
| Tsunoda-Shimizu, H | 1 |
| Hayashi, N | 1 |
| Hamaoka, T | 1 |
| Kawasaki, T | 1 |
| Tsugawa, K | 1 |
| Yagata, H | 1 |
| Kikuchi, M | 1 |
| Suzuki, K | 1 |
| Nakamura, S | 1 |
| Hui, R | 1 |
| Zhang, M | 1 |
| Hao, XM | 1 |
| Zhang, J | 1 |
| Kümmel, S | 1 |
| Vogel, P | 1 |
| Hanusch, C | 1 |
| Eidtmann, H | 1 |
| Hilfrich, J | 1 |
| Gerber, B | 1 |
| Costa, SD | 1 |
| Mehta, K | 1 |
| Kaufmann, M | 1 |
| Puglisi, F | 1 |
| Cardellino, GG | 1 |
| Crivellari, D | 1 |
| Di Loreto, C | 1 |
| Magri, MD | 1 |
| Minisini, AM | 1 |
| Mansutti, M | 1 |
| Andreetta, C | 1 |
| Russo, S | 1 |
| Lombardi, D | 1 |
| Perin, T | 1 |
| Damante, G | 1 |
| Veronesi, A | 1 |
| Martín, M | 1 |
| Rodríguez-Lescure, A | 1 |
| Ruiz, A | 1 |
| Alba, E | 1 |
| Calvo, L | 1 |
| Ruiz-Borrego, M | 1 |
| Munárriz, B | 1 |
| Rodríguez, CA | 1 |
| Crespo, C | 1 |
| de Alava, E | 1 |
| López García-Asenjo, JA | 1 |
| Guitián, MD | 1 |
| Almenar, S | 1 |
| González-Palacios, JF | 1 |
| Vera, F | 1 |
| Palacios, J | 1 |
| Ramos, M | 1 |
| Gracia Marco, JM | 1 |
| Lluch, A | 1 |
| Alvarez, I | 1 |
| Seguí, MA | 1 |
| Mayordomo, JI | 1 |
| Antón, A | 1 |
| Baena, JM | 1 |
| Plazaola, A | 1 |
| Modolell, A | 1 |
| Pelegrí, A | 1 |
| Mel, JR | 1 |
| Aranda, E | 1 |
| Adrover, E | 1 |
| Alvarez, JV | 1 |
| García Puche, JL | 1 |
| Sánchez-Rovira, P | 1 |
| Gonzalez, S | 1 |
| López-Vega, JM | 1 |
| Pache, L | 1 |
| Eiermann, W | 1 |
| Tolcher, AW | 1 |
| Giusti, RM | 1 |
| O'Shaughnessy, JA | 1 |
| Cowan, KH | 1 |
| Zhang, GJ | 1 |
| Adachi, I | 1 |
| Yin, DF | 1 |
| Narabayashi, M | 1 |
| Tokue, Y | 1 |
| Watanabe, T | 1 |
| Kaneko, A | 1 |
| Tsuda, H | 1 |
| Abe, K | 1 |
| Calais, G | 1 |
| Berger, C | 1 |
| Descamps, P | 1 |
| Chapet, S | 1 |
| Reynaud-Bougnoux, A | 1 |
| Body, G | 1 |
| Bougnoux, P | 1 |
| Lansac, J | 1 |
| Le Floch, O | 1 |
| Michaels, BM | 1 |
| Nunn, CR | 1 |
| Roses, DF | 1 |
| Helvie, MA | 1 |
| Joynt, LK | 1 |
| Cody, RL | 1 |
| Pierce, LJ | 1 |
| Adler, DD | 1 |
| Merajver, SD | 1 |
| Willers, H | 1 |
| Würschmidt, F | 1 |
| Janik, I | 1 |
| Bünemann, H | 1 |
| Heilmann, HP | 1 |
| Ferrière, JP | 1 |
| Charrier, S | 1 |
| Curé, H | 1 |
| Kwiatkowski, F | 1 |
| Courtadon, M | 1 |
| Bélembaogo, E | 1 |
| de Latour, M | 1 |
| Achard, JL | 1 |
| Dauplat, J | 1 |
| Chollet, P | 2 |
| Kinney, AY | 1 |
| Sahin, A | 1 |
| Vernon, SW | 1 |
| Frankowski, RF | 1 |
| Annegers, JF | 1 |
| Frye, DK | 1 |
| Dhingra, K | 1 |
| Fowble, B | 1 |
| Hanlon, AL | 1 |
| Patchefsky, A | 1 |
| Freedman, G | 1 |
| Hoffman, JP | 1 |
| Sigurdson, ER | 1 |
| Goldstein, LJ | 1 |
| Gasparini, G | 1 |
| Biganzoli, E | 1 |
| Bonoldi, E | 1 |
| Fanelli, M | 1 |
| Boracchi, P | 1 |
| Mackey, JR | 1 |
| Jennings, LL | 1 |
| Clarke, ML | 1 |
| Santos, CL | 1 |
| Dabbagh, L | 1 |
| Vsianska, M | 1 |
| Koski, SL | 1 |
| Coupland, RW | 1 |
| Baldwin, SA | 1 |
| Young, JD | 1 |
| Cass, CE | 1 |
| Manziuk, LV | 1 |
| Komov, DV | 1 |
| Khaĭlenko, VA | 1 |
| Artamonova, EV | 1 |
| Mikhina, ZP | 1 |
| Ermilova, VD | 1 |
| Abashin, SIu | 1 |
| Moyses, B | 1 |
| Haegele, P | 1 |
| Rodier, JF | 1 |
| Lehmann, S | 1 |
| Petit, T | 1 |
| Velten, M | 1 |
| Schraub, S | 1 |
| Zelek, L | 1 |
| Cottu, P | 1 |
| Tubiana-Hulin, M | 1 |
| Vannetzel, JM | 1 |
| Misset, JL | 1 |
| Chouaki, N | 1 |
| Marty, M | 1 |
| Gamelin, E | 1 |
| Culine, S | 1 |
| Mackenzie, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Adjuvant Chemotherapy in Elderly Patients With Breast Cancer: Weekly Docetaxel vs. CMF[NCT00331097] | Phase 3 | 300 participants (Actual) | Interventional | 2003-07-31 | Completed | ||
| A Prospective Multicenter Open-label, Randomized Phase II Study of Pembrolizumab in Combination With Neoadjuvant EC-Paclitaxel Regimen in HER2-negative Inflammatory Breast Cancer.[NCT03515798] | Phase 2 | 81 participants (Anticipated) | Interventional | 2018-07-24 | Recruiting | ||
| Phase III Trial Assessing the Interest of a Maintenance Chemotherapy Combining Docetaxel (Taxotere) 5-FU After Induction Treatment by Aintensive Chemotherapy for Inflammatory Breast Cancers[NCT02324088] | Phase 3 | 174 participants (Actual) | Interventional | 2000-10-31 | Completed | ||
| Efficacy and Safety of Supplement Adjuvant Capecitabine in Postoperative Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative High-risk Breast Cancer Patients: a Multicenter, Single-arm Clinical Trial[NCT05212454] | Phase 3 | 400 participants (Anticipated) | Interventional | 2023-03-15 | Recruiting | ||
| A Multi-center Randomized Phase III Study Evaluating 4 Cycles of Docetaxel, Doxorubicin and Cyclophosphamide Versus 4 Cycles of Vinorelbine and Capecitabine in Patients Not Sufficiently Responding to 2 Cycles of TAC and 4 Cycles of TAC Versus 6 Cycles of [NCT00544765] | Phase 3 | 2,014 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| An Open-label Randomized Clinical Trial to Compare the Toxicities and Efficacy of Pharmacokinetically-guided and BSA Fixed Dosing Strategy of Docetaxel and Paclitaxel in Chinese Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma, and Breast Cancer Patie[NCT01891123] | 300 participants (Anticipated) | Interventional | 2013-06-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for fluorouracil and Carcinoma, Lobular
| Article | Year |
|---|---|
Arterial thrombosis associated with granulocyte-macrophage colony-stimulating factor (GM-CSF) administration in breast cancer patients treated with dose-intensive chemotherapy: a report of two cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcino | 1995 |
Eyelid metastasis from breast cancer showing marked response to chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Lobular | 1995 |
Lobular carcinoma of the male breast.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Lobular; Combined Modal | 1994 |
24 trials available for fluorouracil and Carcinoma, Lobular
| Article | Year |
|---|---|
Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; BRCA2 Prote | 2020 |
A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 2020 |
German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcino | 2013 |
Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; C | 2015 |
Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast N | 2015 |
UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Axilla; Carc | 2015 |
UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Axilla; Carc | 2015 |
UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Axilla; Carc | 2015 |
UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Axilla; Carc | 2015 |
Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brea | 2017 |
Variations in gene expression and response to neoadjuvant chemotherapy in breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Duct | 2009 |
Phase II study of neoadjuvant treatment with doxorubicin, docetaxel, and capecitabine (ATX) in locally advanced or inflammatory breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitab | 2010 |
Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecita | 2011 |
TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
Mitotic activity and bone marrow micrometastases have independent prognostic value in node positive breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasm | 2011 |
Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2012 |
Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcino | 2003 |
Adjuvant chemotherapy for elderly patients (> or =70 years) with early high-risk breast cancer: a retrospective analysis of 260 patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; C | 2005 |
Cyclin A as a marker for prognosis and chemotherapy response in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Duct | 2005 |
Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 2006 |
Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2007 |
[Comparison of tolerance and toxicity of CEF-100 regimen versus CEF-60 regimen as adjuvant therapy for breast cancer].
Topics: Adult; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransfer | 2007 |
Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Al | 2008 |
Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Biomark | 2008 |
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biom | 2008 |
The prognostic significance of sialyl-Tn antigen in women treated with breast carcinoma treated with adjuvant chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Neoplasm; Antigens, Tumor-Associated, Carbohydrate; | 1997 |
Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridg | 2002 |
51 other studies available for fluorouracil and Carcinoma, Lobular
| Article | Year |
|---|---|
Association of immunohistochemically defined molecular subtypes with clinical response to presurgical chemotherapy in patients with advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinom | 2013 |
The role of oncoplastic breast surgery in the management of breast cancer treated with primary chemotherapy.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, | 2013 |
[Potential indications for helical tomotherapy in breast cancers].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 2014 |
[A case of metastatic breast carcinoma of the cervical muscles].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Lobular; Deoxycytidine; | 2013 |
Lack of prognostic value of mean corpuscular volume with capecitabine therapy in metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Car | 2014 |
Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Axilla; Bi | 2014 |
Outcomes of immediate perforator flap reconstruction after skin-sparing mastectomy following neoadjuvant chemotherapy.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 2015 |
Prediction of pathological complete response to neoadjuvant chemotherapy by magnetic resonance imaging in breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 2015 |
Characterization of MTAP Gene Expression in Breast Cancer Patients and Cell Lines.
Topics: Adenocarcinoma, Mucinous; Antineoplastic Agents; Azacitidine; Carcinoma, Ductal, Breast; Carcinoma, | 2016 |
Rates of major complications during neoadjuvant and adjuvant chemotherapy for early breast cancer: An off study population.
Topics: Acute Coronary Syndrome; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 2016 |
Goserelin plus tamoxifen compared to chemotherapy followed by tamoxifen in premenopausal patients with early stage-, lymph node-negative breast cancer of luminal A subtype.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2016 |
Combination of shear wave elastography and Ki-67 index as a novel predictive modality for the pathological response to neoadjuvant chemotherapy in patients with invasive breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; | 2016 |
Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Br | 2009 |
[Ovarian metastasis of breast cancer: a case report. Role of cytoreductive surgery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Lobu | 2009 |
Doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil as adjuvant chemotherapy in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcino | 2009 |
The clinical outcome of chemotherapy-induced amenorrhea in premenopausal young patients with breast cancer with long-term follow-up.
Topics: Adult; Amenorrhea; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2010 |
[A case of multicentric breast cancer in which an effect of neoadjuvant chemotherapy had a disparity].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcino | 2010 |
Exclusive alternating chemotherapy and radiotherapy in nonmetastatic inflammatory breast cancer: 20 years of follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachial Plexus Neuropathies; Carcinoma | 2012 |
Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; | 2012 |
Off-label use of oxaliplatin in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast | 2011 |
Is adjuvant chemotherapy useful in lobular breast cancer patients?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Lobular; Chemotherapy, | 2011 |
Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Topics: Adult; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast | 2011 |
[Primary systemic therapy in breast cancer patients (2007-2010)].
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; | 2011 |
[Predictive value of (99)Tc(m)-MIBI scintimammography in evaluation of the efficacy of neoadjuvant chemotherapy in patients with operable breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 2011 |
The role of chemoradiotherapy in patients with unresectable T4 breast tumors.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Proto | 2013 |
The fibroblast growth factor receptor 1 (FGFR1), a marker of response to chemoradiotherapy in breast cancer?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinom | 2012 |
Plasma and tissue proteomic prognostic factors of response in primary breast cancer patients receiving neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Proteins; Brea | 2013 |
Study of chromosome damage in patients with breast cancer treated by two antineoplastic treatments.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; | 2002 |
Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Breast Ne | 2002 |
Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Ca | 2003 |
Estrogen receptor-associated expression of keratinocyte growth factor and its possible role in the inhibition of apoptosis in human breast cancer.
Topics: Adenocarcinoma; Apoptosis; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cell Lin | 2004 |
[Effects of neoadjuvant chemotherapy on estrogen and progesterone receptors and HER-2 in breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 2004 |
Neoadjuvant chemotherapy with infusional 5-fluorouracil, adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer: an early response predicts good prognosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 2005 |
Weekly paclitaxel plus capecitabine in advanced breast cancer patients: dose-finding trial of GOIRC and GOL.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Du | 2006 |
Detection of infraclavicular lymph node metastases using ultrasonography in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma, Du | 2005 |
Neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with systemic chemotherapy in patients with breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 2006 |
Clinically occult cutaneous metastases.
Topics: Aged; Aged, 80 and over; Anastrozole; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormon | 2006 |
t(8;16) AML developed subsequent to breast cancer therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone M | 2006 |
Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biopsy, Fine-Needle; Breast Neo | 2007 |
Concomitant intensive chemoradiotherapy induction in non-metastatic inflammatory breast cancer: long-term follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 2007 |
Determining the morphological features of breast cancer and predicting the effects of neoadjuvant chemotherapy via diagnostic breast imaging.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carci | 2008 |
Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tum | 1994 |
Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcino | 1994 |
Locally advanced breast carcinoma: accuracy of mammography versus clinical examination in the prediction of residual disease after chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, | 1996 |
[Combined breast-preserving surgery, chemotherapy and radiotherapy in the treatment of breast carcinoma. Effect of the interval between surgery and the beginning of radiotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 1997 |
Adjuvant chemotherapy with doxorubicin-containing regimen for 326 stage II breast cancers: 15-year results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 1997 |
The presence of proliferative breast disease with atypia does not significantly influence outcome in early-stage invasive breast cancer treated with conservative surgery and radiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neopl | 1998 |
Angiogenesis sustains tumor dormancy in patients with breast cancer treated with adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 2001 |
Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers.
Topics: Affinity Labels; Animals; Antibodies, Monoclonal; Antibody Formation; Antimetabolites, Antineoplasti | 2002 |
[Combination therapy of patients with locally advanced breast cancer].
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop | 2001 |
Assessment of response by breast helical computed tomography to neoadjuvant chemotherapy in large inflammatory breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Al | 2002 |